AU2015215630B2 - Crystalline forms of dolutegravir sodium - Google Patents

Crystalline forms of dolutegravir sodium Download PDF

Info

Publication number
AU2015215630B2
AU2015215630B2 AU2015215630A AU2015215630A AU2015215630B2 AU 2015215630 B2 AU2015215630 B2 AU 2015215630B2 AU 2015215630 A AU2015215630 A AU 2015215630A AU 2015215630 A AU2015215630 A AU 2015215630A AU 2015215630 B2 AU2015215630 B2 AU 2015215630B2
Authority
AU
Australia
Prior art keywords
dolutegravir sodium
crystalline
sodium form
powder
crystalline dolutegravir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015215630A
Other languages
English (en)
Other versions
AU2015215630A1 (en
Inventor
Satish BEERAVELLY
Ramakoteswara Rao Jetti
Madhu Murthy Nadella
Haribabu NANDIPATI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of AU2015215630A1 publication Critical patent/AU2015215630A1/en
Application granted granted Critical
Publication of AU2015215630B2 publication Critical patent/AU2015215630B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2015215630A 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium Ceased AU2015215630B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN455/MUM/2014 2014-02-07
PCT/IB2015/050841 WO2015118460A1 (en) 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium
IN455MU2014 IN2014MU00455A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-02-07 2015-02-04

Publications (2)

Publication Number Publication Date
AU2015215630A1 AU2015215630A1 (en) 2016-09-22
AU2015215630B2 true AU2015215630B2 (en) 2018-08-16

Family

ID=53777379

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015215630A Ceased AU2015215630B2 (en) 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium

Country Status (7)

Country Link
US (1) US10087193B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP3102582A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2015215630B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112016018056A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2938103C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014MU00455A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2015118460A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956662A1 (en) * 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
EP3337479B1 (en) * 2015-08-19 2023-12-13 Laurus Labs Limited Novel polymorphs of dolutegravir and salts thereof
WO2017046131A1 (en) * 2015-09-15 2017-03-23 Ratiopharm Gmbh Processes for preparing solid state forms of dolutegravir sodium
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
KR102722927B1 (ko) * 2017-06-30 2024-10-28 비이브 헬쓰케어 컴퍼니 조합물 및 이의 용도 및 치료
US20210040116A1 (en) 2017-09-07 2021-02-11 Cipla Limited New Polymorphs of Dolutegravir Sodium
US12227518B2 (en) * 2019-02-05 2025-02-18 Msn Laboratories Private Limited, R&D Center Crystalline polymorphs of sodium (4R,12AS)-9-{[(2,4-difluorophenyl) methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido [1′,2′:4,5]pyrazino[2,1-b][1,3]oxazin-7-olate and process for preparation thereof
CN114213432B (zh) * 2021-12-31 2023-02-17 瑞孚信江苏药业股份有限公司 度鲁特韦的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068253A1 (en) * 2008-12-11 2010-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
WO2015019310A1 (en) * 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068253A1 (en) * 2008-12-11 2010-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
WO2015019310A1 (en) * 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof

Also Published As

Publication number Publication date
CA2938103C (en) 2021-08-10
BR112016018056A2 (pt) 2017-08-08
US10087193B2 (en) 2018-10-02
CA2938103A1 (en) 2015-08-13
EP3102582A1 (en) 2016-12-14
IN2014MU00455A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-25
US20160347766A1 (en) 2016-12-01
AU2015215630A1 (en) 2016-09-22
WO2015118460A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
AU2015215630B2 (en) Crystalline forms of dolutegravir sodium
RU2716260C2 (ru) Кристаллическая форма бисульфатного ингибитора jak-киназы и способ ее получения
WO2016038532A1 (en) Amorphous treprostinil diethanolamine
US20190241530A1 (en) Crystal form of ozanimod, and preparation method and pharmaceutical composition thereof
WO2016135755A1 (en) Amorphous apremilast, premixes thereof, and novel crystalline forms of apremilast
WO2015092752A1 (en) Novel crystalline form of dolutegravir sodium
WO2015139591A1 (zh) 德罗格韦钠盐的晶型及其制备方法
AU2015373104A1 (en) Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
CN106458886A (zh) 药物活性化合物的固体形式
EP2714683A2 (en) Amorphous ritonavir co-precipitated
US20210355137A1 (en) Polymorphic forms of bictegravir and its sodium salt
US20110189280A1 (en) Dosage form comprising 1-isopropyl-4-hexahydro-1h-1,4-diazepine or a salt thereof
RU2730521C2 (ru) Винорелбина монотартрат и его фармацевтическое применение
US20180030038A1 (en) Polymorphic Forms of Afatinib Dimaleate
WO2016147206A1 (en) Process for the preparation of amorphous idelalisib and its premix
JP6450840B2 (ja) ５−クロロ−ｎ−（｛（５ｓ）−２−オキソ−３−［４−（５，６−ジヒドロ−４ｈ−［１，２，４］トリアジン−１−イル）フェニル］−１，３−オキサゾリジン−５−イル｝メチル）チオフェン−２−カルボキシアミド メタンスルホネートの新規結晶形態および前記結晶形態を含む医薬組成物
US20150080420A1 (en) Amorphous form of lopinavir and ritonavir mixture
WO2014174529A2 (en) Polymorphs of avanafil
WO2014013505A2 (en) Amorphous vildagliptin
WO2017093789A1 (en) Polymorphic forms of afatinib dimaleate
HK40016752A (en) Crystalline form of gcc-4401c and pharmaceutical composition comprising the crystalline form
CN109535151B (zh) 对甲苯磺酸替扎尼定晶型a及其制备方法和用途
CN116367836A (zh) Hm30181甲磺酸盐的多晶态
CN109535150B (zh) 苯乙酸替扎尼定晶型a及其制备方法和用途
HK40016752B (en) Crystalline form of gcc-4401c and pharmaceutical composition comprising the crystalline form

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired